209 related articles for article (PubMed ID: 23971660)
21. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
22. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
23. [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
Moudden MK; Ziadi T; Al Bouzidi A; Ouarssani A; Hadri L; El Baaj M
Rev Pneumol Clin; 2014 Dec; 70(6):362-5. PubMed ID: 25131364
[TBL] [Abstract][Full Text] [Related]
24. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
Fabrizi F; Aghemo A; Moroni G; Passerini P; D'Ambrosio R; Martin P; Messa P
Dig Dis Sci; 2014 Mar; 59(3):691-5. PubMed ID: 24318802
[No Abstract] [Full Text] [Related]
25. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Leung Y; Urbanski SJ; Schindel L; Myers RP
Can J Gastroenterol; 2006 Oct; 20(10):661-3. PubMed ID: 17066158
[TBL] [Abstract][Full Text] [Related]
26. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
Oiso N; Sato M; Kawada A
J Dermatol; 2013 Sep; 40(9):772-3. PubMed ID: 23855823
[No Abstract] [Full Text] [Related]
27. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
Iwasaki Y; Ikeda F; Yamamoto K
Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
[No Abstract] [Full Text] [Related]
28. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
29. Interferon-associated combined branch retinal artery and central retinal vein obstruction.
Rubio JE; Charles S
Retina; 2003 Aug; 23(4):546-8. PubMed ID: 12972771
[No Abstract] [Full Text] [Related]
30. Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.
Sood A; Midha V; Sandhu JS; Sood N; Kaur A; Mittal R; Puri S
Indian J Gastroenterol; 2010 Jun; 29(3):124-5. PubMed ID: 20803821
[No Abstract] [Full Text] [Related]
31. Side effects of therapy for chronic hepatitis C.
Russo MW; Fried MW
Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
[No Abstract] [Full Text] [Related]
32. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
33. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
Goto T; Ohshima S; Miura K; Shibuya T; Sato W; Dohmen T; Kamada K; Kanata R; Sakai T; Chiba M; Sugimoto Y; Minami S; Ohnishi H
Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
[TBL] [Abstract][Full Text] [Related]
34. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M
Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
[No Abstract] [Full Text] [Related]
35. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
Callens S; Bottieau E; Michielsen P; Colebunders R
AIDS; 2004 Jan; 18(1):131. PubMed ID: 15090841
[No Abstract] [Full Text] [Related]
36. Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege.
Ito T; Suzuki T; Funakoshi A; Tokura Y
Eur J Dermatol; 2014; 24(5):631-3. PubMed ID: 25115439
[No Abstract] [Full Text] [Related]
37. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
Lin J; Lott JP; Amorosa VK; Kovarik CL
J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
[No Abstract] [Full Text] [Related]
38. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186
[No Abstract] [Full Text] [Related]
39. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
40. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
Kim ET; Kim LH; Lee JI; Chin HS
Jpn J Ophthalmol; 2009 Nov; 53(6):598-602. PubMed ID: 20020238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
